| BRO |
Report |
Adjusted EPS |
BEAT |
pred ~$1.10 vs. cons $1.08 |
MEDIUM |
| BRO |
Report |
Total revenue |
IN-LINE |
pred ~$1.73B vs. cons $1.72B |
MEDIUM |
| BRO |
Report |
Organic revenue growth (incl. contingents) |
IN-LINE |
pred ~1.5% vs. cons ~1.5% |
LOW |
| BRO |
Guide |
2H26 organic growth ramp (upper-bound framing) |
UNCHANGED |
guide ~2.0-2.5% vs. cons ~2.5% (2H26) |
MEDIUM |
| BRO |
Guide |
FY26 organic growth |
LOWER |
guide ~1.5% vs. cons ~2.0% (FY26) |
LOW |
| BRO |
Guide |
FY26 contingent commissions |
BETTER |
guide ~$270M vs. cons ~$258M (FY26) |
LOW |
| BRO |
Guide |
Adjusted EBITDAC margin |
UNCHANGED |
guide ~36.8% vs. cons ~36.7% (Q2/FY26) |
MEDIUM |
| BRO |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.5% |
— |
LOW |
| BRO |
Return |
5-day cumulative residual |
-1.5% (FADE) |
EPS likely beats on strong contingents and Accession scale, but the core-organic 'whole ballgame' stays soft as CAT property rates fall (-15-35%) into the seasonally property-heavy Q2 and the pharmacy-model/litigation drags persist. After a ~20% run off the May lows into the print, the bar is high and much of the 2H re-acceleration hope is already priced. Even on a headline beat, the out-period math (continued property softness, ~2.5% capped organic) prompts sell-side to trim 2H/FY organic and revenue estimates, so an initial modest pop fades over the week. |
LOW |